HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
Reviewing HCW Biologics (NASDAQ:HCWB) and ImmunityBio (NASDAQ:IBRX)
Analyzing Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) & HCW Biologics (NASDAQ:HCWB)
HCW Biologics (NASDAQ:HCWB) Trading Down 7.1% – Here’s What Happened
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
HCW Biologics to Participate in the 2025 Maxim Growth Summit
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
HCW Biologics Announces 1-for-40 Reverse Stock Split
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
Why Is Penny Stock HCW Biologics Surging On Monday?
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights